CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ROCKVILLE, Md., Jan. 12, 2022 -- (Healthcare Sales & Marketing Network) -- Cellular Biomedicine Group Inc. (CBMG or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today ann... Biopharmaceuticals, Regenerative Medicine, Oncology, FDA Cellular Biomedicine Group, CAR-T
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | Lymphoma | Marketing | Non-Hodgkin's Lymphoma | Pharmaceuticals